{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18(9)"],"submitter":["Leroux-Roels G"],"pubmed_abstract":["The human papillomavirus type 16/18 (HPV-16/18) AS04-adjuvanted cervical cancer vaccine is licensed for females aged 10 years and above and is therefore likely to be coadministered with other licensed vaccines, such as hepatitis B. In this randomized, open-label study, we compared the immunogenicity of the hepatitis B vaccine administered alone (HepB group) or with the HPV-16/18 AS04-adjuvanted vaccine (HepB+HPV group) in healthy women aged 20 to 25 years (clinical trial NCT00637195). The hepatitis B vaccine was given at 0, 1, 2, and 12 months (an accelerated schedule which may be required by women at high risk), and the HPV-16/18 vaccine was given at 0, 1, and 6 months. One month after the third dose of hepatitis B vaccine, in the according-to-protocol cohort (n = 72 HepB+HPV; n = 76 HepB"],"journal":["Clinical and vaccine immunology : CVI"],"pagination":["1510-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3165228"],"repository":["biostudies-literature"],"pubmed_title":["Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine."],"pmcid":["PMC3165228"],"pubmed_authors":["De Boever F","Leroux-Roels G","Levy J","David MP","Haelterman E","Licini L","Descamps D","Maes C","Dobbelaere K"],"additional_accession":[]},"is_claimable":false,"name":"Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine.","description":"The human papillomavirus type 16/18 (HPV-16/18) AS04-adjuvanted cervical cancer vaccine is licensed for females aged 10 years and above and is therefore likely to be coadministered with other licensed vaccines, such as hepatitis B. In this randomized, open-label study, we compared the immunogenicity of the hepatitis B vaccine administered alone (HepB group) or with the HPV-16/18 AS04-adjuvanted vaccine (HepB+HPV group) in healthy women aged 20 to 25 years (clinical trial NCT00637195). The hepatitis B vaccine was given at 0, 1, 2, and 12 months (an accelerated schedule which may be required by women at high risk), and the HPV-16/18 vaccine was given at 0, 1, and 6 months. One month after the third dose of hepatitis B vaccine, in the according-to-protocol cohort (n = 72 HepB+HPV; n = 76 HepB","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Sep","modification":"2025-04-26T10:22:29.313Z","creation":"2019-03-27T00:43:33Z"},"accession":"S-EPMC3165228","cross_references":{"pubmed":["21734063"],"doi":["10.1128/cvi.00539-10","10.1128/CVI.00539-10"]}}